XML 63 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
NET REVENUES (Tables)
 12 Months Ended
Dec. 31, 2017
NET REVENUES  
Schedule of net revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Year Ended December 31

 

    

2017

    

2016

    

2015

 

 

U.S dollars in thousands

Licensing

 

 —

 

100

 

 —

Commercialization of product

 

3,240

 

 —

 

 —

Promotional services 

 

767

 

 —

 

 —

Other Revenues

 

 —

 

 1

 

 3

 

 

4,007

 

101

 

 3

 

a)

In 2016 the Company recorded revenues with respect to RIZAPORT®.

 

In 2017 the Company recorded revenues with respect to the commercialization of EnteraGam® initiated in June 2017 and promotional activities of Donnatal®  initiated in June 2017 and Esomeprazole Strontium Delayed-Release Capsules 49.3 mg initiated in September 2017.